Adage Capital Partners
IPHA

Adage Capital Partners’s Innate Pharma IPHA Stock Holding History

Adage Capital Partners’s Portfolio IPHA Stock Details IPHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-500,000
Closed -$3.42M – 789
2020
Q2 		$3.42M Hold
500,000
– – 0.01% 657
2020
Q1 		$3.34M Buy
500,000
+300,000
+150% +$2.02M 0.01% 617
2019
Q4 		$1.29M Buy
+200,000
New +$1.23M ﹤0.01% 672

Other funds holding IPHA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Adage Capital Partners's IPHA Position: Q3 2020 in Review

Adage Capital Partners sold out of Innate Pharma (IPHA) in Q3 2020, closing a stake of 500,000 shares — an estimated $3.42M sold.

Adage Capital Partners first reported a position in IPHA in Q4 2019 and held it in 3 quarters. The position peaked at $3.42M in Q2 2020. 6 funds tracked by Wall St. Rank hold IPHA as of Q3 2020.

  • Adage Capital Partners reported no remaining Innate Pharma position as of Q3 2020 after selling out during the quarter.
  • Adage Capital Partners sold 500,000 Innate Pharma shares in Q3 2020, an estimated $3.42M.
  • Adage Capital Partners first reported a position in Innate Pharma in Q4 2019 and held it in 3 quarters.
  • Adage Capital Partners's Innate Pharma position peaked at $3.42M in Q2 2020.
  • 6 funds tracked by Wall St. Rank held Innate Pharma as of Q3 2020.

Based on Adage Capital Partners's 13F filing for Q3 2020, filed 16 Nov 2020.